ERBB2 and glioblastoma: As early as 2016, a study revealed the potent and selective antitumor activity of CAR-NK cells, which target the growth factor receptor tyrosine kinase ErbB2 (HER2), against GBM cells in both in vitro and in situ GBM xenograft models [77].